Navigation Links
Derma Sciences Announces Date of Its First Quarter 2008 Earnings Release and Conference Call on May 15, 2008
Date:5/7/2008

PRINCETON, N.J., May 7 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bullentin Board: DSCI), provider of advanced wound care products, announced plans to release its first quarter 2008 results before market on Thursday, May 15, 2008. The Company will hold a conference call that same day to discuss the results at 11:00 am EDT. Interested parties should call 866 202 4683 (domestic) or 617 213 8846 (international), with passcode 26916332 to access the call. You may also access this call via the Internet at:

http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=1830398

For those who are unavailable to listen to the live broadcast, a replay will be available through June 15, 2008 and can be accessed by dialing 888 286 8010 (domestic) and 617 801 6888 (international) and using passcode is 80070508.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand - the licensor of the patented honey- based technology - and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in variety of wounds and burns, and was recently the focus of a large scale randomized controlled trial on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com .

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermascie
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
2. Dermatologists identify North Texas leishmaniasis outbreak
3. Tissue-Growth Gene Tied to Scleroderma
4. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
5. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
6. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. Dermatologists Warn Fitness Enthusiasts: Dont Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity
11. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 1Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 2Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 1Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 2Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 3Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 4Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 5Natural Alternatives International Inc Announces Filing of Patent Infringement Lawsuit 6158 1Natural Alternatives International Inc Announces Filing of Patent Infringement Lawsuit 6158 2